share_log

RBC Capital Reiterates Outperform on Ligand Pharmaceuticals, Maintains $130 Price Target

RBC Capital Reiterates Outperform on Ligand Pharmaceuticals, Maintains $130 Price Target

RBC资本重申对ligand pharmaceuticals的表现良好评级,维持130美元的目标价。
Benzinga ·  08/07 13:13  · 评级/大行评级

RBC Capital analyst Douglas Miehm reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and maintains $130 price target.

RBC资本分析师Douglas Miehm重申Ligand Pharmaceuticals(纳斯达克LGND)的跑赢市场表现,维持价格目标130美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发